The Global Premenstrual Syndrome Treatment Market is estimated to grow at a CAGR of around 3.7% during the forecast period, i.e., 2024-30.
Key Findings of the Study: Premenstrual Syndrome Treatment Market
Global Premenstrual Syndrome Treatment Market Driver: Growing Instances of Premenstrual Dysphoric Disorder (PMDD) Driving Market Growth
Globally, the instances of PMDD emerged as one of the major market drivers, which has been growing significantly, which is in particular due to the growing fitness issues among women. PMDD is the greater extreme shape of premenstrual syndrome, which often results in excessive bodily abnormalities, like belly pain, weight pain, swelling of breasts, and so forth. Also, the predominant aspect besides PMDD is intense hormonal balance, which is frequently related to the genetics of women. Further, consistent stress and other neurological conditions may also affect the hormonal balance among women, leading to PMDD. Henceforth, as the instances of PMDD have been escalating, the demand for treatment solutions has also amplified, which has been driving the market growth. This demand is also expected to grow in the forecast years, as the instance of PMDD would increase further.
Access Free Sample Report – https://www.marknteladvisors.com/query/request-sample/premenstrual-syndrome-treatment-market.html
Scope of the Report and Premenstrual Syndrome Treatment Market Segmentation
By Drug Type
-Analgesics
-Antidepressants
-Oral Contraceptives
-Ovarian Suppression Agents
-Others (Diuretics, Herbal Supplements, etc.)
- Out of them all, the oral contraceptives segment held a major market share.
By Type
-Prescription
-Over-the-Counter (OTC)
By Distribution Channel
-Hospital Pharmacies
-Retail Pharmacies
-Online Pharmacies)
Top leading companies in the Premenstrual Syndrome Treatment Market includes:
Bayer AG, Pfizer Inc., Zydus Cadila, Alkem Laboratories Ltd., Kobayashi Pharmaceutical Co., Ltd., Haleon Group of Companies, Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., Asarina Pharma AB, Lupin, Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd. (Accord Healthcare), Ova Moon, AstraZeneca plc, and others
Premenstrual Syndrome Treatment Market Development
- 2022: Lupin received the US Food and Drug Administration approval for the generic oral contraceptive pill Drospirenone.
For more detailed information about the Premenstrual Syndrome Treatment market report, click here – https://www.marknteladvisors.com/research-library/premenstrual-syndrome-treatment-market.html
Geographical analysis:
North America: The US, Canada, Mexico
Europe: Germany, The UK, France, Italy, Spain, Rest of Europe
Asia-Pacific: China, Japan, Australia, South Korea, India, Rest of Asia-Pacific
South America: Brazil, Rest of South Americ
Middle East & Africa: The UAE, South Africa, Saudi Arabia, Rest of the Middle East & Africa
- North America has been experiencing substantial growth in the Premenstrual Syndrome Treatment Industry in the past few years.
Note: If you require specific information not covered in the current report, we can provide it through customized option
Related Reports: –
Why choose Us?
MarkNtel Advisors is a leading consulting, data analytics, and market research firm that provides an extensive range of strategic reports on diverse industry verticals. We being a qualitative & quantitative research company, strive to deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, and individuals, among others.
For Media Inquiries, Please Contact:
Call: +1 628 895 8081 | +91 120 4278433
Email: sales@marknteladvisors.com
Sales Office: 564 Prospect St, B9, New Haven, Connecticut, USA-06511
Corporate Office: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, India
